Protalix BioTherapeutics, Inc. PLX 41.96
Health Care · NYSE · Data as of 2026-08-12
Protalix BioTherapeutics, Inc. (PLX) has delivered +16.0% annualized revenue growth, n/a earnings growth, and n/a dividend growth over 10 years of data. Ranked #1339 of 1983 stocks overall and #164 of 263 in the Health Care sector by Steady Score.
Industry
Biological Products
Steady Score
41.96
Overall Rank
#1339 / 1983
Sector Rank
#164 / 263
Revenue CAGR
+16.0%
Earnings CAGR
-
Dividend CAGR
-
?
E/R CAGR Ratio
-
Revenue
Earnings
Dividends
Free Cash Flow
Margin
NET Margin
FCF Margin
Payout Ratio
Payout Ratio
FCF Payout Ratio